<SEC-DOCUMENT>0001213900-20-035691.txt : 20201109
<SEC-HEADER>0001213900-20-035691.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201109061054
ACCESSION NUMBER:		0001213900-20-035691
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20201109
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		201295985

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea129529-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of November 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton
South, Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;&#9746;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>Form
40-F&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#9746;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published one announcement
(the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on November 9, 2020 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD>&ldquo;US DoD NMRC Reports Positive Response to Vaccine&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Public Notice is attached
as an exhibit to this report on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the
exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 8%; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Exhibit</B><BR>
<B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 91%; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><BR>
<B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea129529ex99-1_immuron.htm"><FONT STYLE="font-size: 10pt">US DoD NMRC Reports Positive Response to Vaccine</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><IMG SRC="image_001.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;November 9, 2020</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Company Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea129529ex99-1_immuron.htm
<DESCRIPTION>US DOD NMRC REPORTS POSITIVE RESPONSE TO VACCINE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US
DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Points</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NMRC
                                         demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and
                                         ETEC </B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
                                         executes a Research Agreement with PCI Clinical Services to manufacture drug product</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Two
                                         human phase II clinical trials to be conducted in 2021 by the US NMRC</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>One
                                         trial will focus ETEC infections </B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
                                         second trial will focus on the ability of the hyperimmune product to protect volunteers
                                         against moderate to severe campylobacteriosis</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne,
Australia, November 09, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing
and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce
that the Naval Medical Research Center (NMRC) has completed the characterisation of the colostrum harvested from cows immunized
with the experimental vaccine developed to target Campylobacter and Enterotoxigenic E.coli (ETEC). The NMRC confirmed that the
conjugated vaccine produced a robust immunological response in cows and reported that the new Hyper-immune therapeutic contains
high levels of antibodies which specifically target <I>Campylobacter jejuni</I> capsule and <I>Enterotoxigenic Escherichia coli
</I>(ETEC) colonization factor antigen 1 (CFA/1). These are key antigenic targets predicted to be protective against diarrhea
induced by both pathogens. The US DoD noted that the colostrum contained high levels of specific immunoglobulins against the target
antigens in the vaccine and furthermore, was shown to contain functional antibodies capable of inducing hemoglutination inhibition
of the CFA/1 specific ETEC strain to be used in one of the two planned controlled human infection-model clinical trials scheduled
for next year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCI
Clinical Services has been contracted to manufacture the drug product against <I>Campylobacter </I>and ETEC for clinical evaluation
by the US Department of Defense. The manufacturing campaign is scheduled to commence this month and be completed by the end of
2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work
on the Investigational New Drug (IND) application and the clinical protocols for evaluating the safety and efficacy of the product
in moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections is progressing well. The NMRC
plans to file the IND application with the U.S. Food and Drug administration (FDA) in Q1 2021. The ability of the new hyperimmune
product to protect volunteers from moderate to severe campylobacteriosis and ETEC disease will be assessed during two inpatient
clinical trials planned for Q2 and Q3 2021. A total of 60 volunteers divided into two inpatient cohorts will be enrolled in the
study and randomly assigned to either Cohort 1 <I>C. jejuni</I> or Cohort 2 ETEC controlled human infection models.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1.5pt solid; width: 31%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3, 62 Lygon Street,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carlton South, Victoria</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AUSTRALIA 3053</P></TD>
    <TD STYLE="border-top: Black 1.5pt solid; width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.immuron.com</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABN: 80 063 114 045</P></TD>
    <TD STYLE="border-top: Black 1.5pt solid; width: 36%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Phone: + 61 (0)3 9824 5254</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Facsimile: + 61 (0)3 9822 7735</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 34%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; width: 33%"><IMG SRC="ex99-1_002.jpg" ALT=""></TD></TR>
</TABLE></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infectious
diarrhea is the most common illness reported by military personnel deployed overseas and by travelers visiting developing countries.
Diarrhea morbidity decreases daily performance, affects judgment, decreases morale and declines operational readiness. In addition,
travelers' diarrhea is now also recognized by the medical community to result in post-infectious sequalae, including post-infectious
Irritable Bowel Syndrome and several post-infectious autoimmune diseases. The US Department of Defense has recognized the burden
of infectious diarrhea and has heavily invested in the development of effective vaccines for their prevention. However, despite
robust research efforts made to develop vaccines against major enteric pathogens, there are currently no licensed vaccines available.
Development of an effective, safe, and affordable prophylactic agent to control infectious diarrhea would offer a useful product
for travelers and military personnel going to high-risk areas in Latin America, Africa, the Middle East, and Asia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
major goal of this research effort is to lay the scientific foundation for development of a multi-pathogen anti-diarrheal colostrum
supplement that confers protection against <I>Campylobacter jejuni</I> and ETEC, the predominant causes of infectious diarrhea
in travelers visiting developing countries and among military personnel deployed overseas. Ultimately, the data resulting from
these studies will provide military policymakers with information needed to make decisions on product acquisition and stocking.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release has been authorised by the directors of Immuron Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY
                                         CONTACT:</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr
        Jerry Kanellos, Ph.D.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Executive Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
        +61 (0)3 9824 5254</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@immuron.com</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Immuron</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally
delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel
and safe technology platform with one commercial asset generating revenue. In Australia, Travelan&reg; is a listed medicine on
the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is a licenced natural health
product (NPN 80046016) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as
a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelan&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan<SUP>&reg;
</SUP>is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo;
diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan&reg;
is a highly purified preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia, Travelan<SUP>&reg;
</SUP>is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk
of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg;
is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S.,
Travelan<SUP>&reg;</SUP> is sold as a dietary supplement for digestive tract protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 3</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 34%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; width: 33%"><IMG SRC="ex99-1_002.jpg" ALT=""></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelers&rsquo; diarrhea</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelers&rsquo;
diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal
cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli
</I>(ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The
more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the
causative agent of cholera) are often confused with travelers&rsquo; diarrhea as they may be contracted while travelling and initial
symptoms are often indistinguishable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: http://www.immuron.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product development programs and any other statements that are not historical
facts. Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the
early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual
property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations
or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Page
3 of 3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !+ $$# 2(  A$! Q$!_\0
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MJ]XM^,]S;0_L@?\ !.W]MS]H'1]1@DFTOXE>,O WA_\ 9>^$5UY3*LA'B_\
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/&;@D#!(]*?0 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 10# 2(  A$! Q$!_\0
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M._M9>"/V/_!=GX@\=ZC/IFEW]XMC#+%:R7!:4JS ;4!(X4\U^+O_  1:./\
M@HI\//\ KA??^D<E?=O_  <1#/[)'A7_ +&F'_T1-7Z%FO"."PV?X?*X2E[.
MHE=MJ^KDM-+=.Q\3EW$V*KY-6S":CSP;MH[:)>?GW/H[X8?\%&?A!\6OA'XB
M\=:;XLAMO"WA6<6VI7U_!):)#(5#*H#@%B01@*"2>!7C6A?\%V/A#XS^+NB^
M$M TSQAJLFN:C#IMO??85@M]\KA WSN'VY/]W/M7X[>!T\7?$^WTOX<>'UO]
M436=76ZM-'M^EU>L@C$A'0E4'4\*-QK]&?V7/^""/B'X<^*_"WC3QC\0-,TV
M_P##^H6^K2Z;861GB3RG$AC:=V4=L%@N![UZ^8\(9!E2F\?6=Y7Y(WUM;2]E
M=Z]=%T/,P/$^<YDXK!4E96YWTWUM=]NFKZGZ2?%/XL>&O@?X"U+Q1XOUS3/#
MGA[2(C/>:A?SK#! @]6/?T Y)X )K\UOCA_P=A_ ?X>>+)=.\(^&/&_Q!M8&
MVMJ5I#'8VLOO'YY#L/<J*_/S_@HW^UO\4_\ @NW^WY#\*/A9;W6I>"M&U&6S
M\.:7%(8[.=86*3:O>-T"]2I;A$V@ LQS^A/[)7_!L%\!/@'X CU3XR7,WQ(\
M0PQ>?J$]W>/I^BV6!EA'$C*2@Y^>1B2.PZ5\W3R7+,NHQJ9NW*I-74([I>?_
M  Z[:GZ?[L5>1T?[*'_!S_\ L\_M"^([;1?%*Z_\*M2O'$<,NO1I)ISL3@*;
MF(E4SQRZJ/4U^C6F:G;:UIT%Y9W$%W:74:RPSPR"2.9&&596'!!!R".M?C_\
M<_\ @EG_ ,$_/VLO$DG@[X:>+++X=>/;LFWTZXT2ZGEL+B<\"-HYLPRY/&%=
M2>QJ+_@CY\;/BS_P2^_:[U/]CKXTK+JUCJ5I+JGP[O5GS;WFP,[06LDF/W4J
MJY6-CF.5"G&ZL<SR+"SINK@HSIS2YG3J*S<?YHM[I==]#DPV.PN*@YX6HII:
M/E:E9]M+Z^1^QE%<Y\,OBOHGQ=T.:^T2Z\X6EP]G>6\B&.XL+A/OPS1GYDD7
MN#Z@C((-,^,OQ6TOX&_"GQ!XOUJ3R]+\.6,M]<'."P120H]V.%'N17R'L*GM
M/96?->UNMS15Z;I^U4ER[WZ6,OX]_M*^!OV8?!YUSQUXCT_P_8$E8O/?,MRW
M]V.,9=S[*#[U\CZY_P '"GP8T_66@L]%\<ZE:J<?:DL(XU;W"M(&Q^%?F'\8
M?BW\0O\ @HE^TNM_/!>ZWXE\1W7V31M(@.4L(224@B'155>6<XSAF)K[)\!_
M\&Y?B75?!B7'B/XD:;I&NRQ[OL5EIINK>!L?=:5G4MZ$J,>F:_5EPAD>548?
MV[6?M)=%T^23?S=EV/SI\39OF-67]CTE[./5]?O:7RW/N[]EW_@I+\(OVN[\
M:=X3\3(FN;-_]D:C$;2]([[4;A\=]A:O=Z_G;_:Q_8[^(/[ OQ8L+#Q 3;S;
M_M>B:_IDC+#=%"/GB?ADD4XRIY&1U!S7Z^_\$E?VWKG]M#]G#S->ECD\9>$I
METW6'4;?M?RYBN<=O,4'/^TK5X7%'"-#!X:.9Y;4]I0E\VK[:Z75].C3T9Z_
M#W$U7$XB6 Q\.2LOQ^7?KV:U/J>BBBO@3[,*_G2^/?\ R?KXK_['V7_TNK^B
MVOYTOCW_ ,GZ^*_^Q]E_]+J_5/"W^-BO\"_,_._$+^%A_P#$?OC^U#,T'[,W
MQ"=&*NOAK42".H/V62OP^_X) :%#X@_X*$_"^.:$3K;SSW:J1G:\=K*RM^!&
M:_;_ /:G_P"38?B)_P!BSJ/_ *2R5^*G_!%+_E(K\//^O:__ /2*6IX(DXY%
MF37\O_MLA\6*^;X!/^;_ -NB?O37Y2?\''WAV"W\<_"S5U51<W-E?V3L!RR(
M\3J#]"[?F:_5NORT_P"#D7_C^^$?TU/^5O7@>'[:SZC;^]_Z2SV>-4GD]6_]
MW_TI'KG_  ;W^%K;2OV+M8U2- +K5_$]T)WQRPBCB1!^ )_.ONV2,2QE6 96
M&""."*^)?^" ?_)A;_\ 8SZA_**OMRO.XN;>=8EO^=G=PTDLJH)?RH_G(T33
MX_#7[<5I:68\J&P\?+#"%XV*NHX 'X5^\7[<\[VW[&GQ1=&*L/#%_@@]/W#U
M^$9_Y/S/_90__<C7[L_MW?\ )E_Q2_[%B_\ _1#U][Q\V\7E[?9?G$^,X,_W
M;&I?UI(_'#_@BIH]OJ__  44\!K<1+*MK:WUS&&&=LB6K[6^HS7[SU^$?_!$
M#_E(OX+_ .P=J/\ Z2M7[N5Y'BBW_:T%_<7YR/4\/%_PF2?]]_E$_(O_ (.,
M_#UO9_'GX=:G'&JW-]H=S!,X'+K'."N?IYC5]-_\$"O#$&B_L&)?)$JSZSK]
M]/+)WDV,L2Y^@2OG/_@X\_Y*G\+O^P7??^C8J^H/^"$W_*/#0?\ L+:E_P"E
M+5W9K.7^I6&_Q?K,X\NBO];,1_A_2!]@7UE'J5C-;S()(9T:.12,AE(P0?P-
M?SK?LWVBZ#^WAX)M[?\ =):>/+>&,#^!5OMH'Y<5_1=7\Z_P+_Y2!^%?^RAQ
M?^G"L_#AOV&.CTY%^4C3CI?OL&_[_P"L3]I?^"K'_*.[XL?]@1O_ $8E?FG_
M ,$!O^3[Y_\ L6KO_P!#BK]+?^"JJ&3_ ()X?%@#_H",?_(B5^:/_! B9$_;
MQD5G57D\-7FQ3U<AXB0/PYJN&/\ DE<?\_\ TF)/$/\ R46#^7YL_;"N*_:2
M_P"3=O'O_8N:A_Z325VM<)^U#?Q:7^S5\09YW$<4?AO4"S'L/LTE?F>$_CP]
M5^9]_B?X4O1_D?B=_P $6_\ E(I\//\ KC??^D<E?=__  <0_P#)H_A;_L:8
M?_1$U?"/_!%E"W_!17X>X'2"^)]O]#DK[N_X.(?^32/"W_8TP_\ HB:OVCB+
M_DL,'Z1_.1^4Y)_R2^*]7^43P/\ X-W?@W:^)_CIXV\:W<$<TGA;3H;"R9AD
MPS7+,7<>A\N,K]'-?>W_  5>^)6H_"'_ ()M?&KQ#I$GDZC8>$[T02=XS(GE
M[A[@.2/>OEK_ (-OHE'PN^*;X&XZS9J3CG MV_QK[-_;S^ TW[3_ .QC\3OA
M_:MMO/%7AV[L;4^LYC)B!]BX4'ZU\7QEB>;B63K?#%P7R2BW^I]GP72C3RBD
MUUNW][/@G_@U-_9!TKX7?L4:A\6)[5'\3?$B_EMXKEE&^#3K5S%'$IZ@-*LC
MMZG;Z"O.O^"LO[<7BG]K+X[:C\+/ XU6\\(>&KEK26STN-YI-<NT.))'" EH
MD;*JO3(+'J,?1_\ P;]_$,R?\$8=%MXHVMM:\"?VUI%_;MQ);7EO/,Y5AU!^
M=>#7J_\ P2'^#7AGX4_L3^'O%\267]M>,K637-<U>0*))&=W8JTAY"1@8QG
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ME/%?3]<'$U:G6S7$5:34HN3::V9V9!2G2RZC3J*TE%73/YSC_P GYG_LH?\
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MR^#_  1X.CG;PC97GV'32RD>?&6#75^Z_P (V(=N>BJ.[8KZ^_X+PZ1!X?\
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MK2+5-1BM7N0I 8H'8;L%E!QZCUKY+_X*EC/[;7['O_8Z3?\ HRRKSS_@M/\
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M"I%V7-=:ZO6*V1-+#4E3JPPV#E3E*$E=\O;;23W9Z+_P3H_Y,.^$7_8J:?\
M^B%KP/\ X*<-:_$[]MO]EKP+:2/-J]MXH?Q!=0PC<]O:P^6WF-Z*3$W7LIKD
MO ?_  3[_;&^''A'2O#NC?M#>&=,T+1[>.RM+:&Q+"V@0!552UN2<*.,GMUK
MW7]C/_@G)'^SM\3-5^(WC3QAJ?Q)^)^LPFUEUJ^78EK <?NXDR<9  )STX
MSG"7U+ XNKF,<3&I)\_+&*E>\DTKMQ225[O5[6-H_6L7AJ>"E0E!+EYG*UK1
M:;M9MMNUCZ<HHHKX<^K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  = %X# 2(  A$! Q$!_\0
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>[]+:V2_FOOTWW6F#I8R,H^U;\]K=;]7Y6^>VS__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
